Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Doxorubicin inhibits human DNA topoisomerase I.

Foglesong PD, Reckord C, Swink S.

Cancer Chemother Pharmacol. 1992;30(2):123-5.

PMID:
1318169
2.

DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.

Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschenbaum S, Silber R, Potmesil M.

Cancer Res. 1989 Nov 1;49(21):5969-78.

3.

[Anthracycline antibiotics and their derivatives--inhibitors of topoisomerase I].

Dezhenkova LG, Teviashova AN, Olsuf'eva EN, Treshchalin ID, Shtil' AA, Preobrazhenskaia MN.

Bioorg Khim. 2008 May-Jun;34(3):430-2. Russian.

PMID:
18672696
4.

Protection against Adriamycin cytotoxicity and inhibition of DNA topoisomerase II activity by 3,4-dihydroxybenzoic acid.

De Graff WG, Myers LS Jr, Mitchell JB, Hahn SM.

Int J Oncol. 2003 Jul;23(1):159-63.

PMID:
12792789
5.

Characterization of a potent catenation activity of HeLa cell nuclei.

Holden JA, Low RL.

J Biol Chem. 1985 Nov 25;260(27):14491-7.

6.

Mechanisms of resistance to drugs that inhibit DNA topoisomerases.

Beck WT, Danks MK.

Semin Cancer Biol. 1991 Aug;2(4):235-44. Review.

PMID:
1655118
7.

Cytotoxicity and inhibitory properties against topoisomerase II of doxorubicin and its formamidine derivatives.

Kik K, Studzian K, Wasowska-Ɓukawska M, Oszczapowicz I, Szmigiero L.

Acta Biochim Pol. 2009;56(1):135-42. Epub 2009 Feb 23.

8.
9.
11.

Various inhibitors of DNA topoisomerases diminish repair-specific DNA incision in UV-irradiated human fibroblasts.

Thielmann HW, Popanda O, Gersbach H, Gilberg F.

Carcinogenesis. 1993 Nov;14(11):2341-51.

PMID:
8242865
12.
13.

Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I.

Bridewell DJ, Finlay GJ, Baguley BC.

Oncol Res. 1997;9(10):535-42.

PMID:
9507531
14.
15.

Dihydrobetulinic acid induces apoptosis in Leishmania donovani by targeting DNA topoisomerase I and II: implications in antileishmanial therapy.

Chowdhury AR, Mandal S, Goswami A, Ghosh M, Mandal L, Chakraborty D, Ganguly A, Tripathi G, Mukhopadhyay S, Bandyopadhyay S, Majumder HK.

Mol Med. 2003 Jan-Feb;9(1-2):26-36.

16.

In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.

Wang Y, Eksborg S, Lewensohn R, Lindberg A, Liliemark E.

Anticancer Drugs. 1999 Nov;10(10):921-8.

PMID:
10630360
17.
20.

Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II.

Wassermann K, Markovits J, Jaxel C, Capranico G, Kohn KW, Pommier Y.

Mol Pharmacol. 1990 Jul;38(1):38-45.

PMID:
2164630

Supplemental Content

Support Center